6.2.3.1.4. neoadjuvant adjuvant hormone therapy plus radiotherapy. combination rt luteinising hormone releasing hormone (lhrh) adt superiority compared rt alone followed deferred adt relapse, shown phase iii rcts [675-685] (table 6.1.9). main message intermediate-risk disease short duration four six months optimal longer one, 2-3 years, needed high-risk patients. largest rct intermediate risk disease comparing dose escalated rt without six months adt failed demonstrate os advantage median follow-up time 6.3 years. six months adt use associated reduced psa failure, fewer distant metastases improved prostate cancer specific mortality . table 6.2.9: selected studies use duration adt combination rt pca studytnm stagentrialadtrteffect osrtog 85-31 2005 t3 n1 m0977ebrt ± adtorchiectomy lhrh agonist 15% rp65–70 gysignificant benefit combined treatment(p = 0.002) seems mostly caused patients isup grade group 2-5rtog 94-13 2007 t1c–4 n0–1m01,292adt timing comparison2 mo.neoadjuvantplus concomitant vs.4 mo. adjuvantsuppressionwhole pelvicrt vs.prostateonly; 70.2 gyno significant difference neoadjuvant plus concomitant vs. adjuvant androgen suppression therapy groups (interaction suspected)rtog 86-10 2008 t2–4 n0–1456ebrt ± adtgoserelin plusflutamide2 mo. before, plusconcomitanttherapy65–70 gy rtno significant difference 10 yr.d’amico av, et al. 2008 t2 n0 m0 (localised unfavourable risk)206ebrt ± adtlhrh agonist plus flutamide 6 mo.70 gy 3d-crtsignificant benefit may pertain men minimal co-morbidity(hr: 0.55, 95% ci: 0.34-0.90, p = 0.01)rtog 92-02 2008 t2c–4 n0–1 m01554short vs. prolonged adtlhrh agonistgiven 2 yr.as adjuvantafter 4 mo. asneoadjuvant65–70 gyp = 0.73,p = 0.36 overall; significant benefit(p = 0.044) (p = 0.0061)in subset isup grade 4–5eortc 22961 2009 t1c–2ab n1 m0, t2c–4 n0–1 m0970short vs. prolonged adtlhrh agonist 6 mo. vs. 3 yr.70 gy 3d-crtbetter result 3 yr. treatment with6 mo. (3.8% improvement survival 5 yr.)eortc 22863 2010 t1–2 poorly differentiated m0, t3–4 n0–1 m0415ebrt ± adtlhrh agonist 3 yr. (adjuvant)70 gy rtsignificant benefit 10 yr. combined treatment (hr: 0.60, 95% ci: 0.45–0.80,p = 0.0004).trog 96-01 2011 t2b–4 n0 m0802neoadjuvant adt durationgoserelin plus flutamide 3 6 mo. before, plus concomitant suppression66 gy 3d-crtno significant difference os reported; benefit pca-specific survival(hr: 0.56, 95% ci:0.32–0.98, p = 0.04)(10 yr.: hr: 0.84,0.65–1.08, p = 0.18)rtog 99-10 2015 intermediate risk94% t1–t2, 6% t3–41,579short vs. prolonged adtlhrh agonist 8 + 8 vs. 8 + 28 wk.70.2 gy 2d/3d67 vs. 68%, p = 0.62, confirms 8 + 8 wk.lhrh standardpcsiii2020 intermediate risk60076 gy alone vs.76 gy + adtvs.70 gy + adtlhrh + bicalutamide6 mo.4 mo. prior rt70 vs. 76 gysignificantly improved biochemical failure-free pca-specific survival adt arms, difference os.rtog 08152023 intermediate risk1,492dose escalated rt ± adtlhrh agonist/antagonist + bicalutamide flutamide6 mo.2 mo.prior rt79.2gy (89%)45gy + bt boost(11%)no difference os.significantly improved biochemical failure-free, metastatic-free survival pca-specific survival adt arm. adt = androgen deprivation therapy; ci = confidence interval; ebrt = external beam radiotherapy standardfractionation; hr = hazard ratio; isup = international society urological patholohy; lhrh = luteinising hormone-releasing hormone; mo. = months; n = number patients; os = overall survival; rp = radical prostatectomy;rt = radiotherapy; bt = brachytherapy; wk = week; yr. = year; 3d-crt = three-dimensional conformal radiotherapy. question added value ebrt combined adt clarified 3 rcts. showed clear benefit adding ebrt long-term adt (table 6.1.10). table 6.2.10: selected studies adt combination with, without, rt pca studytnm stagentrial designadtrteffect osspcg-7/sfuo-3 2016 t1b-2 grade 1-3, t3 n0 m0875adt ± ebrtlhrh agonist 3 mo. plus continuous flutamide70 gy 3d-crt vs. rt34% (95% ci: 29-39%) vs. 17% (95% ci: 13-22% csm 12 (15) yr. favouring combined treatment (p < 0.0001 15-yr. results) ncic ctg pr.3/mrcpro7/ncic 2015 t3-4 (88%), psa > 20 ng/ml (64%), isup grade group 4-5 (36%) n0 m01,205adt ± ebrtcontinuous lhrh agonist65–70 gy 3d-crt vs. rt10-yr. os = 49% vs. 55% favouring combined treatment hr: 0.7, p < 0.001)sargos, et al., 2020 t3-4 n0 m0273adt ± ebrtlhrh agonist 3 yr.70 gy 3d-crt vs. rtsignificant reduction clinical progression; 5-yr. os 71.4% vs. 71.5% adt = androgen-deprivation therapy; csm = cancer-specific mortality; ebrt = external beam radiotherapy;hr = hazard ratio; lhrh = luteinising hormone-releasing hormone; mo. = months; n = number patients;os = overall survival; psa = prostate-specific antigen; rt = radiotherapy; 3d-crt = three-dimensional conformal radiotherapy; yr = years.